The Hardest Drugs to Make
Oncology is consistently the largest therapeutic area in pharmaceutical development pipelines, and it is consistently the most technically demanding. The molecules tend to be highly potent. The patient populations are often defined by specific biomarkers, requiring precise clinical supply and diagnostic coordination. The tolerability window is narrow, making dose accuracy and product consistency critically important. And the speed imperative is real: patients with advanced cancers cannot afford the delays that are merely inconvenient in other therapeutic areas.
A CDMO that works well for a standard oral solid in cardiovascular disease may not be equipped for an oncology programme. The containment requirements, the analytical sensitivity demands, the clinical supply complexity, and the regulatory scrutiny are all substantially higher.
The Technical Demands of Oncology Drug Development
High-Potency Handling
Most small molecule oncology drugs are cytotoxic or have high pharmacological potency. Occupational exposure limits in the nanogram per cubic metre range require engineering controls, dedicated manufacturing suites, and validated decontamination procedures that are a significant capital and operational investment. Not all CDMOs have them.
Bioavailability Challenges
Many kinase inhibitors, PARP inhibitors, and other targeted oncology agents are BCS Class II or IV molecules with poor aqueous solubility. Getting adequate bioavailability to support efficacious plasma exposures often requires amorphous solid dispersion technology, nanosuspension, or lipid-based formulation. The CDMO must have these capabilities in-house, and they must be compatible with HPAPI handling if the API requires it.
Bioanalytical Complexity
Oncology clinical trials require sophisticated bioanalytical programmes. PK characterisation across a wide dose range. Pharmacodynamic biomarkers that demonstrate target engagement. Immunogenicity testing for biologic oncology agents. Cell-based assays for cell therapy programmes. A CDMO with integrated bioanalysis can manage all of these as a coherent programme; a CDMO without bioanalysis capability requires the sponsor to manage a separate vendor relationship.
What Oncology Programmes Need from a CDMO Partner
| Requirement | Why It Matters in Oncology | Ardena Capability |
| HPAPI manufacturing at OEB 4-5 | Cytotoxic small molecules and ADC payloads require strict containment | Pamplona: OEB 3-5 containment; isolators; validated decontamination |
| ASD formulation for BCS Class II/IV | Many targeted oncology agents have poor oral bioavailability | Somerset and Pamplona: spray drying and HME |
| Aseptic fill-finish for cytotoxic injectables | IV oncology formulations require sterile manufacturing with HPAPI controls | Ghent: aseptic fill-finish; HPAPI-compatible sterile suite |
| ADC bioanalysis (total Ab, conjugated Ab, free payload) | ADCs require multi-analyte PK characterisation | Assen: LBA and LC-MS/MS for full ADC PK panel |
| Biomarker and flow cytometry assays | Companion diagnostics and PD biomarkers are central to oncology trial design | Assen: MSD multiplex; multi-parametric flow cytometry |
| CMC regulatory expertise for oncology | Oncology programmes often use accelerated pathways with higher CMC scrutiny | Multi-site regulatory team; experience with Breakthrough Therapy and PRIME designations |
| Small-batch GMP for rare tumour subtypes | Patient populations in oncology trials can be very small | All sites: clinical batch capability without minimum batch size constraints that force waste |
Speed Without Shortcuts
Oncology drug development operates under genuine time pressure. Patients with limited treatment options are waiting. But the speed imperative does not justify cutting corners that create problems later. A poorly characterised solid form that requires reformulation at Phase II. A stability programme that does not cover the clinical trial duration. A CMC package that triggers a regulatory hold.
The fastest programmes are not the ones that skip steps. They are the ones that identify the critical path clearly, run parallel workstreams where the science allows, and avoid the rework that comes from doing development in the wrong order. That requires a partner with enough experience in oncology to know which steps can be accelerated and which cannot.
How Ardena Serves Oncology Programmes
Ardena’s network covers the full oncology development and manufacturing chain. HPAPI capability at Pamplona, ASD formulation at Somerset and Pamplona, sterile manufacturing at Ghent, and integrated bioanalysis at Assen give oncology sponsors a single partner across the technical domains their programmes require. The project management model, with a single project manager coordinating work across sites, means the sponsor is not left to manage four separate CDMO relationships.
